Finanzen von CG Oncology Inc (CGON)CGONCG Oncology Inc

Evaluating the bottom line, CG Oncology, Inc. maintains a gross margin of -239.24%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -7467.68%, while the net margin is -6832.84%. These profitability ratios, combined with a Return on Equity (ROE) of -26.41%, provide a clear picture of how effectively CGON converts its operational activities into shareholder value.

In the context of the broader market, CGON competes directly with industry leaders such as SRRK and COGT. With a market capitalization of $7.00B, it holds a leading position in the sector. When comparing efficiency, CGON's gross margin of -239.24% stands against SRRK's N/A and COGT's N/A. Such benchmarking helps identify whether CG Oncology, Inc. is trading at a premium or discount relative to its financial performance.

CG Oncology has shown substantial revenue growth, with Q2 2026 revenue at $1,157,000, but continues to report significant net losses, with a net income of -$79,056,000. Gross margin has turned negative, indicating challenges in cost management.